Alan S Plotzker1,2, Rachel L Henson1,2, Anne M Fagan1,2, John C Morris1,2, Gregory S Day3. 1. The Charles F. and Joanne Knight Alzheimer Disease Research Center, St. Louis, MO, USA. 2. Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA. 3. Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.
Abstract
BACKGROUND: Cerebral amyloid angiopathy with related inflammation (CAA-ri) is a rare age-associated disorder characterized by an inflammatory response to amyloid in cerebral blood vessels. CAA-ri is often treated with corticosteroids, but response to treatment is variable. OBJECTIVE: To assess the relationship between clinical and paraclinical measures and outcomes in patients with CAA-ri treated with high doses of methylprednisolone. METHODS: Longitudinal clinical course, and results from serum and cerebrospinal fluid (CSF) testing, electroencephalography, and neuroimaging were reviewed from 11 prospectively-accrued CAA-ri patients diagnosed, treated, and followed at Barnes Jewish Hospital (St. Louis, MO, USA). Magnetic resonance imaging (MRI) changes were quantified using a scoring system validated in cases of amyloid related imaging abnormality (ARIA-E). Clinical outcomes were assessed as change in modified Rankin Scale (ΔmRS) from baseline to final assessment (median 175 days from treatment with high doses of methylprednisolone; range, 31-513). RESULTS: Worse outcomes following methylprednisolone treatment were associated with requirement for intensive care unit admission (median ΔmRS, 5 versus 1.5; p = 0.048), CSF pleocytosis (median ΔmRS 4.5 versus 1; p = 0.04), or lower CSF Aβ40 at presentation (rho = -0.83; p = 0.02), and diffusion restriction (median ΔmRS 4 versus 1.5; p = 0.03) or higher late ARIA-E scores (rho = 0.70; p = 0.02) on MRI, but not preexisting cognitive decline (median ΔmRS 2 versus 2; p = 0.66). CONCLUSION: Clinical and paraclinical measures associated with outcomes may inform clinical counseling and treatment decisions in patients with CAA-ri. Baseline cognitive status was not associated with treatment responsiveness.
BACKGROUND: Cerebral amyloid angiopathy with related inflammation (CAA-ri) is a rare age-associated disorder characterized by an inflammatory response to amyloid in cerebral blood vessels. CAA-ri is often treated with corticosteroids, but response to treatment is variable. OBJECTIVE: To assess the relationship between clinical and paraclinical measures and outcomes in patients with CAA-ri treated with high doses of methylprednisolone. METHODS: Longitudinal clinical course, and results from serum and cerebrospinal fluid (CSF) testing, electroencephalography, and neuroimaging were reviewed from 11 prospectively-accrued CAA-ri patients diagnosed, treated, and followed at Barnes Jewish Hospital (St. Louis, MO, USA). Magnetic resonance imaging (MRI) changes were quantified using a scoring system validated in cases of amyloid related imaging abnormality (ARIA-E). Clinical outcomes were assessed as change in modified Rankin Scale (ΔmRS) from baseline to final assessment (median 175 days from treatment with high doses of methylprednisolone; range, 31-513). RESULTS: Worse outcomes following methylprednisolone treatment were associated with requirement for intensive care unit admission (median ΔmRS, 5 versus 1.5; p = 0.048), CSF pleocytosis (median ΔmRS 4.5 versus 1; p = 0.04), or lower CSF Aβ40 at presentation (rho = -0.83; p = 0.02), and diffusion restriction (median ΔmRS 4 versus 1.5; p = 0.03) or higher late ARIA-E scores (rho = 0.70; p = 0.02) on MRI, but not preexisting cognitive decline (median ΔmRS 2 versus 2; p = 0.66). CONCLUSION: Clinical and paraclinical measures associated with outcomes may inform clinical counseling and treatment decisions in patients with CAA-ri. Baseline cognitive status was not associated with treatment responsiveness.
Authors: Osvaldo Laurido-Soto; Matthew R Brier; Laura E Simon; Austin McCullough; Robert C Bucelli; Gregory S Day Journal: J Neurol Date: 2018-12-17 Impact factor: 4.849
Authors: Fabrizio Piazza; Steven M Greenberg; Mario Savoiardo; Margherita Gardinetti; Luisa Chiapparini; Irina Raicher; Ricardo Nitrini; Hideya Sakaguchi; Monica Brioschi; Giuseppe Billo; Antonio Colombo; Francesca Lanzani; Giuseppe Piscosquito; Maria Rita Carriero; Giorgio Giaccone; Fabrizio Tagliavini; Carlo Ferrarese; Jacopo C DiFrancesco Journal: Ann Neurol Date: 2013-04-26 Impact factor: 10.422
Authors: Leslie M Shaw; Magdalena Korecka; Michal Figurski; Jon Toledo; David Irwin; Ju Hee Kang; John Q Trojanowski Journal: J Appl Lab Med Date: 2020-01-01
Authors: Eitan Auriel; Andreas Charidimou; M Edip Gurol; Jun Ni; Ellis S Van Etten; Sergi Martinez-Ramirez; Gregoire Boulouis; Fabrizio Piazza; Jacopo C DiFrancesco; Matthew P Frosch; Oct Vio M Pontes-Neto; Ashkan Shoamanesh; Yael Reijmer; Anastasia Vashkevich; Alison M Ayres; Kristin M Schwab; Anand Viswanathan; Steven M Greenberg Journal: JAMA Neurol Date: 2016-02 Impact factor: 18.302
Authors: Henrik Zetterberg; Tobias Skillbäck; Niklas Mattsson; John Q Trojanowski; Erik Portelius; Leslie M Shaw; Michael W Weiner; Kaj Blennow Journal: JAMA Neurol Date: 2016-01 Impact factor: 18.302